Dendritic Cell Cancer Vaccine for High-grade Glioma (GBM-Vax)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by Trimed Biotech GmbH.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Trimed Biotech GmbH
ClinicalTrials.gov Identifier:
NCT01213407
First received: May 28, 2010
Last updated: October 1, 2010
Last verified: October 2010
  Purpose

A randomised, open-label, 2-arm, multi-centre, phase II clinical study with one group receiving standard therapy with Temozolomide, radiotherapy, and Trivax; and a control group receiving standard therapy with Temozolomide and radiotherapy only; after tumour resection of at least 70% in both groups. The hypothesis is based on the assumption that time to progression will be doubled in the treatment group.


Condition Intervention Phase
Glioblastoma Multiforme
Drug: Trivax, Temozolomide, Surgery, Radiotherapy
Drug: Temozolomide, Surgery, Radiotherapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: First Line Standard Therapy of Glioblastoma Multiforme With or Without add-on Treatment With Trivax, an Anti-tumour Immune Therapy Based on Tumour-lysate Charged Dendritic Cells

Resource links provided by NLM:


Further study details as provided by Trimed Biotech GmbH:

Primary Outcome Measures:
  • Progression free survival [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Progression free survival measured as percentage of non-progressive patients with newly diagnosed GBM 12 months after a post-operative MRI scan treated according to the current standard (surgical resection, irradiation, oral chemotherapy with Temozolomide), and Trivax, an autologous DC cancer vaccine charged with autologous tumour protein, as add-on therapy (group A), in comparison to patients receiving standard treatment without Trivax (group B).


Secondary Outcome Measures:
  • Quality of Life [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Quality of life in patients treated with Trivax as an add-on therapy using ECOG (Eastern Cooperative Oncology Group) performance status compared to quality of life of patients receiving standard therapy (for study patients older 18 years).

  • Progression free survival at 18 and 24 months [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Progression free survival measured as percentage of non-progressive patients at 18 and 24 months post initiation of treat-ment.

  • Overall survival [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    The percentage of survival will be assessed at 12, 18, and 24 months.


Estimated Enrollment: 56
Study Start Date: March 2010
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Standard therapy plus Trivax
Standard therapy with Surgery, Temozolomide, and Radiotherapy; plus Trivax, 5x10e6 autologous interleukine-12 secreting dendritic cells charged with autologous tumour lysate.
Drug: Trivax, Temozolomide, Surgery, Radiotherapy

Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32

Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy

Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.

Break: weeks 7, 8, 9, 10.

Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31.

Other Name: Temodal
Active Comparator: Standard therapy
Surgery, Temozolomide, Radiotherapy
Drug: Trivax, Temozolomide, Surgery, Radiotherapy

Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32

Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy

Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.

Break: weeks 7, 8, 9, 10.

Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31.

Other Name: Temodal
Drug: Temozolomide, Surgery, Radiotherapy

Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy

Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6

Break: weeks 7, 8, 9, 10

Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31

Other Name: Temodal

  Hide Detailed Description

Detailed Description:

Vaccination represents a success story in modern medicine and its principles have been found to be valid in different species, at least in the case of infectious diseases. As of today, there is little reason to believe that this would not be true in the case of tumours. It is now generally acknowledged that human tumours carry a mutational antigenic (non-self) repertoire of immunogenic potential that may be a suitable target for antitumour immune therapy. During the last years accumulating evidence from mouse experiments indicates that one can immunise prophylactically against cancers as effectively as against an infectious agent. However, in contrast to most experimental mouse tumour models, human tumours have in general been within their host for a long time and thus had the opportunity to influence their microenvironment and the larger immunological environment. Antigens capable of mediating specific rejection were found in human as well as in mouse tumours.

Many of the clinical trials using dendritic cell (DC) -based cancer vaccination techniques were designed for the treatment of melanoma. Other important diseases in which DC-based cancer vaccination was studied include prostate cancer, B cell lymphoma, renal cell carcinoma, glioma and glioblastoma, breast and ovarian cancer, gastrointestinal cancer, and selected solid paediatric tumours. In most of these trials some in vivo and/or in vitro evidence for the generation of anti-tumour immunity was found and even complete or partial remission of the tumour was observed in selected cases. The first phase III trial demonstrating the efficacy of DC cancer vaccination for the treatment of prostate cancer was reported recently (www.dendreon.com). Also patients suffering from glioblastoma multiforme appear to benefit from DC cancer immune therapy. The side effects observed in DC cancer vaccinations were usually described to be mild and not limiting the application.

We developed a DC cancer vaccine technology, Trivax, advancing the design of DC cancer immune therapy in one critical aspect. It is the first such vaccine that is enable for releasing the immune modulatory cytokine interleukin (IL) -12. Trivax is comprised of IL-12 secreting DCs and a mixture of protein tumour antigens derived from the individual patient's tumour cells. No synthetic tumour antigen component is involved. Both components of Trivax are derived from the individual patient and are used for the treatment of only this patient. Trivax therefore represents a fully individualised somatic cell therapy medicine. Trimed's early clinical evaluations in patients suffering from kidney cancer, prostate cancer, bone tumours, and malignancies of childhood have confirmed the safety and the feasibility of the Trivax technology.

Glioblastoma multiforme (GBM) (ICD-O M9440/3) is the most malignant astrocytic tumour, composed of poorly differentiated neoplastic astrocytes. Histopathological features include cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, micro-vascular proliferation and necrosis. GBM typically affects patients of various age beginning in childhood and up to high age. It is preferentially located in the cerebral hemispheres. GBM may develop from diffuse astrocytomas WHO grade II or anaplastic astrocytomas (secondary GBM), but more frequently, they manifest after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary GBM). In spite of modern oncological treatment, the prognosis of GBM remains dismal, with a median survival of little over 1 year.

GBM-Vax is a randomised, open-label, 2-arm, multi-centre, phase II clinical study with both groups undergoing surgery and receiving standard therapy with Temozolomide and radiotherapy; and the treatment group that in addition to the standard therapy receives cancer immune therapy with Trivax. Our aim is to extend therapy options presently including surgery, irradiation and Temozolomide with DC cancer vaccination to improve the poor prognosis of patients with GBM.

Primary objective

• Progression free survival measured as percentage of non-progressive patients with newly diagnosed GBM 12 months after a post-operative MRI scan treated according to the current standard (surgical resection, irradiation, oral chemo-therapy with Temozolomide), and Trivax, an autologous DC cancer vaccine charged with autologous tumour protein, as add-on therapy (group A), in comparison to patients receiving standard treatment without Trivax (group B).

Secondary objectives

  • Progression free survival measured as percentage of non-progressive patients with newly diagnosed GBM 18 and 24 months after a post-operative MRI scan receiving standard treatment and Trivax as add-on therapy (group A), in comparison to patients receiving standard treatment without Trivax (group B).
  • Extension of overall survival of patients with newly diagnosed GBM receiving standard treatment and Trivax as add-on therapy, in comparison to patients receiving standard treatment without Trivax.
  • Quality of life in patients treated with Trivax as an add-on therapy using ECOG (Eastern Cooperative Oncology Group) performance status compared to qual-ity of life of patients receiving standard therapy (for study patients older 18 years).

Number of subjects In total, 56 patients will be enrolled in the study. The study consists of 2 arms and at least 28 patients should be randomly assigned to one of the two arms. It is expected to recruit the study patients within a period of one year. Randomisation is based on stratification according to study sites at a 1:1 ratio. Patients younger than 18 years will not be randomised but will all receive add-on therapy with Trivax. We feel that it would be not just to expect from children to understand and accept that there is a new treatment available but only every second patient will receive it. Obviously, patients younger than 18 years will not be analysed together with adult patients in the context of the study; and paediatric patients will not count towards the recruiting number of 2 x 28. Thus, the results obtained in paediatric GBM patients will not influence the outcome of the study in patients older than 18 years.

  Eligibility

Ages Eligible for Study:   3 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female or male, paediatric or adult patients of 3 to 70 years of age at time of diagnosis that qualify for standard treatment including surgery, Temozolomide and radiotherapy.
  • GBM (WHO IV), confirmed by histology.
  • Total, subtotal, or partial resection of more then 70% of tumour mass defined by MRI.
  • Supratentorial tumour localisation.
  • ECOG performance status 0, 1, or 2 (for study patients older 18 years).
  • Life expectancy of at least 12 weeks by assessment of the attending physician.
  • Written informed consent of patient and/or legal guardian in case of children or adolescents.

Exclusion Criteria:

  • Less than 100 µg of tumour protein obtained from the resected tissue.
  • Anti-neoplastic chemotherapy or radiotherapy during 4 weeks before entering the study, e.g. in another therapeutic phase I, II, or III study.
  • Positive pregnancy test or breast-feeding.
  • Patients unwilling to perform a save method of birth control.
  • Known hypersensitivity to temozolomide.
  • HIV positivity.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01213407

Contacts
Contact: Thomas Felzmann, MD, MBA +431 40170 ext 4080 thomas.felzmann@ccri.at

Locations
Austria
Landesnervenklinik Wagner-Jauregg Recruiting
Linz, Oberösterreich, Austria, 4020
Contact: Johanna Buchroithner, MD    +43 (0)50 554/62 ext 25921    johanna.buchroithner@gespag.at   
Contact: Josef Pichler, MD    +43 (0)50 554/62 ext 28556    interneambulanz.wj@gespag.at   
Principal Investigator: Johanna Buchroithner, MD         
Landeskrankenhaus Feldkirch Recruiting
Feldkirch, Austria, 6807
Contact: Karl Roessler, MD    +43 5522 / 303 ext 1901    karl.roessler@lkhf.at   
Principal Investigator: Karl Rössler, MD         
Medical University Innsbruck Recruiting
Innsbruck, Austria, 6020
Contact: Günther Stockhammer, MD    +43-512-504 ext 24368    guenther.stockhammer@i-med.ac.at   
Principal Investigator: Günther Stockhammer, MD         
Kaiser Franz-Josef Spital Recruiting
Vienna, Austria, 1100
Contact: Stefan Oberndorfer, MD    +431 601 91 ext 2061    stefan.oberndorfer@wienkav.at   
Contact: Günther Kleinpeter, MD    +431 711 65 ext 4301    guenther.kleinpeter@wienkav.at   
Principal Investigator: Stefan Oberndorfer, MD         
Donauspital, SMZ-Ost Recruiting
Vienna, Austria, 1220
Contact: Reinhard Ruckser, MD    +431 288 02 ext 3214    reinhard.ruckser@wienkav.at   
Contact: Elvira Kitzweger    +431 288 02 ext 3280    elvira.kitzweger@wienkav.at   
Principal Investigator: Reinhard Ruckser, MD         
Medical University Vienna Recruiting
Vienna, Austria, 1090
Contact: Christine Marosi, MD    +431 40400 ext 4447    christine.marosi@meduniwien.ac.at   
Contact: Cornelia Sax, MSc    +431 40400 ext 4421    cornelia.sax@meduniwien.ac.at   
Principal Investigator: Christine Marosi, MD         
Sponsors and Collaborators
Trimed Biotech GmbH
Investigators
Principal Investigator: Johanna Buchroithner, MD Landesnervenklinik Wagner-Jauregg
  More Information

Additional Information:
Publications:
Responsible Party: Thomas Felzmann, Trimed Biotech GmbH
ClinicalTrials.gov Identifier: NCT01213407     History of Changes
Other Study ID Numbers: GBM-Vax
Study First Received: May 28, 2010
Last Updated: October 1, 2010
Health Authority: Austria: Agency for Health and Food Safety

Keywords provided by Trimed Biotech GmbH:
Dendritic cell
Cancer vaccine
Anti-tumor immune therapy
Interleukine-12
Individualised autologous therapy
Brain cancer
Temozolomide
Radiotherapy
Irradiation
High-grade glioma
Advanced therapy medicinal product ATMP
Somatic cell therapy
Leukocyte apheresis
Neurosurgery
Neurooncology
Neurology
Immunology
Tumor immunology
Transfusion medicine
Monocyte
Killer cell
Cytotoxic T-cell
Cytotoxic T-lymphocyte

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Dacarbazine
Interleukin-12
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors

ClinicalTrials.gov processed this record on August 19, 2014